The indications, contraindications, technique, and complications of bone marrow aspiration and biopsy are to be carefully known by both the patents and the clinicians.
Congratulations Puneet Chandna MD(h.c.), PhD, FIET, FNCCN, MAHA!
The Global Go-getter
You’re an avid traveller, crisscrossing the globe to forge new connections and seal new deals. Your overseas degree puts you many notches above others. You’ve conquered new territories while working with global organizations, reaching new milestones in your professional journey.
In a statement issued late on Friday (American time), the US Trade Representative cited recent steps to remove the threat that had created considerable acrimony between the two governments.
“Over the last few months, there have been multiple engagements with government of India officials at the staff and senior levels on the broad range of issues of concern to the United States and to US stakeholders. India has made useful commitments in recent months, in cluding to institutionalize high-level engagement on IP issues, to pursue a specific work program and to deepen cooperation and information exchange with the US on IPrelated issues under the USIndia Trade Policy Forum,“ the USTR said.
The move comes weeks before US president Barack Obama lands in Delhi as the chief guest for the Republic Day parade, becoming the first American president to attend the event. It follows the first meeting of the US-In dia Trade Policy Forum in four years for which USTR Michael Froman flew to Delhi last month.
“It’s a positive development and it’s the right track to follow. India has a well-established legislative, administrative and judicial framework to safeguard IPR, which meet its TRIPS commitments while utilizing the flexibilities provided in the international regime to address developmental concerns,“ industrial policy and promotion secretary Amitabh Kant told TOI. For the last few years, the pharma industry has been lobbying hard with US authorities to declare India a rogue country for adopting a policy that has waived patent rights for a cancer drug on the grounds of affordability, besides disallowing patents for several medicines citing lack of innovation. The government has countered this by saying that its policies are in line with India’s international commitments.
Apart from the out-of-cycle review by the USTR, the US International Trade Commission (USITC) is also conducting an investigation on India’s policies, including those related to duties and investment.The government has, however, refused to participate in either exercise and termed them unilateral actions.
NEW DELHI: There’s good news for patients. Drug pricing regulator NPPA announced cap on prices of over 25 drugs, including painkillers and antibiotics, which will lead to reduction in their costs over the next few weeks.
The price regulator in a notification issued on December 10, fixed prices of formulations which join a list of 348 essential medicines that were placed under price control. The new drugs on which caps were issued include commonly-used antibiotics and painkillers, as well as medicines used for treating cancer and skin disorders.
The NPPA notification mentions a total of 52 drugs, including those with specific dosage strengths which were till now not under the purview. The latest addition brings the total market size of medicines under price control to nearly Rs 125 crore, according to market research firm AIOCD AWACS. The wide-ranging price cuts will impact both domestic and foreign companies.
The NPPA notification, an industry expert explained, also includes price changes which will be extended on dosage strengths of molecules which were till now not under price control. It said it has fixed/revised the prices in respect of 52 formulation packs — both ceiling and retail price packs under DPCO, 2013. Price caps on some of these drugs only apply to specific companies, it added
Earlier efforts by the NPPA to bring down prices of essential drugs for diseases like cancer, have been strongly opposed. In July, the NPPA in a rare invocation of the lesser-used provision had fixed prices of 50 antidiabetic and cardiovascular medicines. This was the first time that the government had brought drugs, outside the national list of essential medicines, under price control.
The move had triggered of a series of protests and lawsuits from the industry against the drug pricing regulator, as they feared more such action.
Finally, in September this year the government had withdrawn certain powers of the drug pricing regulator that allowed it to cap prices of widely-prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines.
11 lakh Cancer cases in India every year: Govt
Responding to another question, he said that the Delhi Development Authority (DDA) has agreed in principle for allotment of additional land for expansion of trauma centre at AIIMS.
Approximately, 185 cases are received every day in Jai Prakash Narayan Apex Trauma Centre of AIIMS, which has bed strength of 186, he added.